These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15535402)

  • 1. HIV drug resistance testing: is the evidence really there?
    Dunn DT; Gibb DM; Babiker AG; Green H; Darbyshire JH; Weller IV
    Antivir Ther; 2004 Oct; 9(5):641-8. PubMed ID: 15535402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of resistance testing.
    Stebbing J; Gazzard BG
    J HIV Ther; 2002 Nov; 7(4):75-9. PubMed ID: 12733604
    [No Abstract]   [Full Text] [Related]  

  • 3. Resistance tests: what do clinical trials tell us?
    Price N; Smit E; Pillay D
    J HIV Ther; 2002 Nov; 7(4):80-6. PubMed ID: 12733605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
    Narciso P; Lazzarin A
    Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of testing human immunodeficiency virus for drug resistance.
    Harrigan PR; Côté HC
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S117-22. PubMed ID: 10860895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interpretation of resistance assay results.
    Miller V
    Antivir Ther; 2001; 6 Suppl 2():1-9. PubMed ID: 11678473
    [No Abstract]   [Full Text] [Related]  

  • 7. Updated European recommendations for the clinical use of HIV drug resistance testing.
    Vandamme AM; Sönnerborg A; Ait-Khaled M; Albert J; Asjo B; Bacheler L; Banhegyi D; Boucher C; Brun-Vézinet F; Camacho R; Clevenbergh P; Clumeck N; Dedes N; De Luca A; Doerr HW; Faudon JL; Gatti G; Gerstoft J; Hall WW; Hatzakis A; Hellmann N; Horban A; Lundgren JD; Kempf D; Miller M; Miller V; Myers TW; Nielsen C; Opravil M; Palmisano L; Perno CF; Phillips A; Pillay D; Pumarola T; Ruiz L; Salminen M; Schapiro J; Schmidt B; Schmit JC; Schuurman R; Shulse E; Soriano V; Staszewski S; Vella S; Youle M; Ziermann R; Perrin L
    Antivir Ther; 2004 Dec; 9(6):829-48. PubMed ID: 15651743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current insights into reverse transcriptase inhibitor-associated resistance.
    Wainberg MA; White AJ
    Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
    [No Abstract]   [Full Text] [Related]  

  • 9. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
    Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug resistance in antiretroviral therapy of HIV infection].
    Oette M; Häussinger D
    Med Klin (Munich); 2003 Dec; 98(12):692-9. PubMed ID: 14685670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of resistance testing in clinical trial design and product labelling: a regulatory perspective.
    Laessig KA; Murray JS; Chikami G
    Antivir Ther; 2000 Mar; 5(1):77-83. PubMed ID: 10846597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
    Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
    Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
    Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF;
    Antivir Ther; 2006; 11(3):305-14. PubMed ID: 16759046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral resistance.
    Geretti AM
    J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
    [No Abstract]   [Full Text] [Related]  

  • 15. [The impact of resistance testing of HIV-1 to the HIV clinical setting in Japan].
    Yamamoto Y
    Nihon Rinsho; 2002 Apr; 60(4):769-74. PubMed ID: 11968786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limits of resistance testing.
    D'Aquila RT
    Antivir Ther; 2000 Mar; 5(1):71-6. PubMed ID: 10846596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
    Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
    J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisiting the concept of a genetic barrier to resistance.
    Rusconi S
    J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
    [No Abstract]   [Full Text] [Related]  

  • 19. Understanding transmitted HIV resistance through the experience in the USA.
    Taiwo B
    Int J Infect Dis; 2009 Sep; 13(5):552-9. PubMed ID: 19136289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical significance of viral fitness.
    Geretti AM
    J HIV Ther; 2005 Mar; 10(1):6-10. PubMed ID: 15951728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.